Since Leqembi is dosed based on a patient’s weight and offered in single-use vials, about 5.8% of the drug dispensed will be ...

A simple tweak in available vial sizes of the breakthrough Alzheimer's drug Leqembi could save Medicare hundreds of millions ...

Eli Lilly is making a series of investments in China to support its manufacturing and R&D operations. Gilead Sciences has ...

Australia's Therapeutic Goods Administration (TGA) has said it won't approve Eisai and Biogen's Alzheimer's disease therapy ...

“You could see him diminishing.” Today, Carr is trying a new treatment called Leqembi that has been shown to modestly slow the disease for people in the initial stages of Alzheimer’ ...

About 6% of Leqembi (lecanemab) is discarded because patients are frequently prescribed doses lower than the size of the drug’s single-use vials. This waste costs Medicare about $1,600 a patient ...

Even though you cannot stop AD from getting worse, with LEQEMBI, you can take steps to slow how fast it progresses.[3] That's why identifying symptoms early on is so important.[1] "In recent years ...

The UK drugs regulator has approved Eisai and Biogen's Alzheimer's disease therapy Leqembi, shortly after an EU committee turned it down on the grounds that its modest efficacy did not outweigh ...

Biogen (BIIB – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Mohit Bansal ...

Mizuho Securities analyst Salim Syed has maintained their bullish stance on BIIB stock, giving a Buy rating on September 24. Salim Syed has ...